Michael Crowley, Jr. SeraCare is
headquartered in Oceanside, CA and maintains facilities in
Massachusetts, Maryland and Pennsylvania.

pathogens inhibit

Commenting on this addition to the Board of Directors Edward L.----SeraCare Life
Sciences, Inc.getdna. Such factors
include , but are not limited to (i) whether the patent applications
will result in issued patents, (ii) whether the scope of claims in the
patent applications will be materially changed during prosecution of
the patent applications, (iii) whether the subject matter disclosed in
the patent applications can be successfully commercialized by the
Company, (iv) whether patents, if any, that ultimately issue on the
applications will offer any protection against competitors with
competing technologies, and (v) whether the Company will be able to
negotiate satisfactory arrangements with the University of Maryland
with respect to ownership and licensing rights for the technology that
is the subject of the patent applications.

purified blood

The Company undertakes no obligation to publicly update or
revise any forward looking statements, whether as a result of new
information, future events or otherwise .

inhibit lifeshare

There are many therapeutic and diagniostic uses for blood derivatives, plasma proteins and hemapheresis products.

transfusion hemosystem

His combination of industry background and strategic
planning experience will be extremely valuable as the Company and its Board of
Directors address the future.com . We
believe such a designation would add value to their products while
also serving to expand their potential addressable markets worldwide. The Company's
offerings include plasma-based therapeutic products, diagnostic
products and reagents, cell culture products, specialty plasmas, in
vitro stabilizers, and the Global Repository(R), comprised of clinical
samples (DNA, RNA, tissue, and serum) for the application of human
genetics to target validation for drug discovery.

vitex hemoglobin

His most recent position was President of Ortho Clinical
Diagnostics, K.

SeraCare Files Patent Applications for 'Mad Cow' Disease Blood Test

platelets blood

K.immucor.
"In particular, we believe our customers will be able to use this
test to certify that animal or human-based components of their
diagnostic, therapeutic or cell culture products are prion-free.

cst purified

in Japan; a responsibility he held from 1981 until his
retirement in 2002. In
the first stage, the "Mad Cow" prion (essentially a deformed normal
cellular protein) is isolated by binding with a highly specific
antibody.bbii.

cers intravenously

cers hemosystem

For more information please
visit www.

blood cjd

(Nasdaq: BLUD), a global leader in providing automated instrument-reagent
systems to the blood transfusion industry, announced today that Hiroshi (Hiro)
Hoketsu has agreed to join Immucor's Board of Directors effective immediately. SeraCare intends to
commercialize the test, an effort that is expected to commence by
calendar year-end., SeraCare's CEO, commented, "Today's patent
applications underscore the strength of SeraCare's scientific team as
well as our commitment to delivering a growing array of cutting edge
products and services to our life science customers. Such forward looking statements
include (i) the Company's expectations regarding its commercialization
of the Immuno-PCR test , (ii) the Company's belief that the Immuno-PCR
test could prove instrumental in helping to protect the health care
and global life sciences industries from the possible use of
contaminated instruments or materials in a variety of procedures and
processes, (iii) the Company's belief that its customers would be able
to use the Immuno-PCR test to certify that animal or human-based
components of their diagnostic, therapeutic or cell culture products
are prion-free and that such a designation would add both value to
their products while also serving to expand their potential
addressable markets worldwide, and (iv) the Company's belief that the
Immuno-PCR test could serve an important role in screening blood and
organ donors worldwide for nvCJD, similarly to PCR tests that are
currently used for diagnosing hepatitis, HIV, and other viruses.

intravenously circulatory

, Immucor, Inc.

Business Editors/Health /Medical Writers
BIOWIRE2K

OCEANSIDE, Calif.
The Immuno-PCR test will enable the detection of the "Mad Cow"
protein in blood, cerebrospinal fluid, or nerve tissue by combining
two well accepted testing methods: antigen capture and Polymerase
Chain Reaction (PCR), into a two-stage Immuno -PCR testing regimen.

biologics ahf

sterile blood

The antibody/prion complex isolated in the first stage of
the test is then used to amplify the detection signal in the second
stage using the PCR process, thereby creating a sufficient level of
the signal to be accurately measured.

sterile leukocyte

Gallup,
Chairman and Chief Executive Officer, stated , "We are extremely pleased to
have an individual with the expertise and background that Hiro brings to our
Board.com and
www.

serum calibrators

NORCROSS, Ga.
Additionally, we believe the Immuno-PCR test could serve an important
role in screening blood and organ donors worldwide for nvCJD, similar
to PCR tests currently used for diagnosing hepatitis, HIV, and other
viruses.

pathogens transfusions

Mr.

transfusions calibrators

For more information on Immucor, please visit our website
at http://www.

intravenously purified

(NASDAQ:SRLS), an innovative developer and provider of
human and animal based diagnostic, therapeutic and research products
for the life science industry , announced today that it has filed
patent applications in the United States, the European Union, Japan
and Australia for an Immuno-PCR test, a novel blood-based test for
infectious prions, the proteins that cause Creutzfeldt-Jakob Disease
(CJD) or new variant CJD (nvCJD), also known as "Mad Cow" disease in
humans."

About SeraCare Life Sciences:

SeraCare Life Sciences, Inc .com

Safe Harbor For Forward Looking Statements:

Certain statements contained in this press release may be deemed
to be forward looking statements under federal securities laws, and
the Company intends that such forward looking statements be subject to
the safe harbor created thereby .

purified circulatory

Mark Manak, Chief Scientific Officer of BBI Biotech, a division of
SeraCare in Gaithersburg, Maryland, and scientists from the University
of Maryland Institute for Human Virology, could represent a
significant improvement in testing animals or humans for "Mad Cow"
Disease and nvCJD, which was previously identified through post-mortem
analysis of brain/spinal cord tissue. The
Company cautions that these statements are qualified by important
factors that could cause actual results to differ materially from
those reflected by the forward looking statements. Information on these and
additional factors that could affect the Company and its financial
results is included in the Company's report on Form 10-K for the year
ended September 30, 2004 filed with the Securities and Exchange
Commission (SEC) as well as the Company's other periodic filings with
the SEC.

blood hemosystem

Immucor markets a complete family
of automated instrumentation for all of our market segments.

inactivating vitex

Hoketsu has extensive health care experience having been in the industry
since 1967. Hiro was key in taking Ortho direct in the blood banking market in
Japan in 1985 and was instrumental in growing their market share to a
leadership position.

pathogens sera

Immucor Inc. Adds Outside Director to Board

inactivating intravenously

SeraCare believes that the test, which was co-developed by Dr. We believe this
test could prove instrumental in helping to protect the health care
and global life sciences industries from the possible use of
contaminated instruments or materials in a variety of procedures and
processes.

vitex inactivating

"
Founded in 1982, Immucor manufactures and sells a complete line of
reagents and systems used by hospitals , reference laboratories and donor
centers to detect and identify certain properties of the cell and serum
components of blood prior to transfusion. is a manufacturer and provider of
biological products and services for diagnostic, therapeutic, drug
discovery, and research organizations worldwide.